Are Tandem Diabetes Care (NASDAQ:TNDM) Shares a Sell Now? Baird Has Downgraded Stock

September 15, 2018 - By Mona Holcomb

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Logo

Tandem Diabetes Care (NASDAQ:TNDM) Receives a Downgrade

Baird lowered their rating for shares of Tandem Diabetes Care (NASDAQ:TNDM) from “Outperform” to “Neutral” in a note that was issued to clients and investors on Friday, 14 September.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Coverage

Among 8 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Tandem Diabetes Care has $50 highest and $700 lowest target. $33.67’s average target is -29.31% below currents $47.63 stock price. Tandem Diabetes Care had 8 analyst reports since March 23, 2018 according to SRatingsIntel. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Hold” rating given on Tuesday, July 31 by Stifel Nicolaus. The company was upgraded on Friday, March 23 by Robert W. Baird. The firm earned “Neutral” rating on Friday, August 24 by Bank of America. The rating was upgraded by PiperJaffray on Monday, May 14 to “Overweight”. The stock of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has “Buy” rating given on Wednesday, March 28 by Cowen & Co.

The stock decreased 6.92% or $3.54 during the last trading session, reaching $47.63. About 5.19M shares traded or 66.71% up from the average. Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has risen 756.74% since September 15, 2017 and is uptrending. It has outperformed by 741.12% the S&P500.

Analysts await Tandem Diabetes Care, Inc. (NASDAQ:TNDM) to report earnings on October, 25. They expect $-0.39 earnings per share, up 87.38 % or $2.70 from last year’s $-3.09 per share. After $-0.34 actual earnings per share reported by Tandem Diabetes Care, Inc. for the previous quarter, Wall Street now forecasts 14.71 % negative EPS growth.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company has market cap of $2.73 billion. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It currently has negative earnings. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system.

More notable recent Tandem Diabetes Care, Inc. (NASDAQ:TNDM) news were published by: Investorplace.com which released: “Tandem Diabetes Is Firing on All Cylinders” on September 11, 2018, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For September 14, 2018” published on September 14, 2018, Streetinsider.com published: “Pre-Open Movers 09/14: (CSBR) (SHLD) (LPL) Higher; (TLRY) (CRON) (TNDM) Lower (more…)” on September 14, 2018. More interesting news about Tandem Diabetes Care, Inc. (NASDAQ:TNDM) were released by: Benzinga.com and their article: “32 Stocks Moving In Friday’s Mid-Day Session” published on September 14, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: September 14, 2018.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.